Intended for EU healthcare professionals only. The information on this website is not country-specific. This is an international disease awareness campaign.
Back
Infographic

What ASDAS cut-off corresponds best with the need to intensify treatment for patients with axSpA in daily practice?1

Based on a study by Webers C et al. presented at ACR 2023.

Download

Published on

10 Jun 2024
Download

Get similar content directly to your inbox.

Never miss an insight. Register your interest and we'll let you know when new articles are published on this topic

*Reflected by having a balanced specificity and sensitivity.1 

328 patients with axSpA and ≥1 ASDAS measurement in 2016–2022 were selected from a prospective multicentre Dutch registry (SpA-Net). Single patients could contribute multiple treatment intensification events, with only the first observation per patient per calendar year included in the analyses. Only anti-inflammatory drugs (NSAIDs, [b/cs/ts]DMARDs, corticosteroids) were considered with regards to treatment intensification and approximately two-thirds of patients (211/328 [64.3%]) were receiving b/tsDMARDs at some point during the study period.1 

ASAS: Assessment of SpondyloArthritis international Society; ASDAS: Ankylosing Spondylitis Disease Activity Score; axSpA: axial spondyloarthritis; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; (b/cs/ts)DMARD: (biologic/conventional synthetic/targeted synthetic) disease-modifying anti-rheumatic drug; NSAID: non-steroidal anti-inflammatory drug. 

1. Webers C et al. Arthritis Rheumatol. 2023;75(Suppl 9). Abstract 0517. 2. Ramiro S et al. Ann Rheum Dis. 2023;82(1):19–34. 3. Fischer F et al. Healthcare (Basel). 2016;4(3):36.